Physician profile
Steven Sauerberg
NPI 1265454896
$3,383.53
in general payments reported to CMS, 2019-2025
37 companies · $19.64 in 2025
The $19.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $19.72 · 2021: $69.85 · 2022: $22.48 · 2023: $68.75 · 2024: $88.66 · 2025: $19.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $554.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $268.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.94 | 2019 | |
| Pfizer INC. | $255.70 | 2019 | |
| Amgen INC. | $228.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $190.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $187.76 | 2019 | |
| Allergan, INC. | $149.97 | 2019 | |
| Amarin Pharma, INC. | $144.12 | 2019 | |
| Lilly USA, LLC | $142.29 | 2019-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $126.15 | 2019 | |
| Merck Sharp & Dohme LLC | $116.11 | 2019 | |
| Abbvie INC. | $93.71 | 2021-2023 | Botox |
| Radius Health, INC. | $82.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.02 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $54.04 | 2019 | |
| Arbor Pharmaceuticals, INC. | $49.64 | 2019 | |
| Sanofi Pasteur INC. | $47.66 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $39.49 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $33.78 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.64 | 2024 | Caplyta |
| Uswm, LLC | $28.08 | 2023 | Zimhi, Lucemyra |
| Genentech USA, INC. | $26.29 | 2019 | |
| Abbott Laboratories | $20.12 | 2024 | Proclaim |
| Indivior INC. | $19.64 | 2025 | Sublocade |
| Vivus LLC | $17.56 | 2019 | |
| Lundbeck LLC | $17.24 | 2023 | Rexulti |
| Boston Scientific Corporation | $16.25 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.04 | 2024 | Rexulti |
| Kaleo, INC. | $15.18 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.29 | 2019 | |
| Circassia INC. | $14.17 | 2019 | |
| Neos Therapeutics, LP | $14.17 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.45 | 2019 | |
| Glaxosmithkline, LLC. | $11.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.88 | 2019 | |
| Eisai INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sauerberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.